STAAR Surgical (STAA) vs Warby Parker (WRBY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Warby Parker (WRBY) has outperformed STAAR Surgical (STAA) over the past year, gaining 26.5% versus a loss of 13.5%. Over five years, WRBY leads with a -56.6% price change compared with -75.1% for STAA. Warby Parker is the larger company by market cap ($2.87 billion vs $1.22 billion), about 2.4 times the size.
On valuation, STAAR Surgical trades at a lower forward P/E (21.4x vs 36.4x for Warby Parker). Warby Parker converts more of its revenue into profit, with a net margin of 0.2% versus -33.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | STAA | WRBY |
|---|---|---|
| Share price | $24.22 | $23.12 |
| Market cap | $1.22B | $2.87B |
| 1-day change | -3.24% | -4.19% |
| YTD return | +4.89% | +6.10% |
| 1-year return | -13.50% | +26.48% |
| 5-year return | -75.08% | -56.64% |
| P/E ratio (TTM) | — | 385.33 |
| Forward P/E | 21.39 | 36.44 |
| EPS (TTM) | $0.01 | $0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $239.44M | $871.90M |
| Revenue growth (YoY) | -23.72% | +13.04% |
| Net income (latest FY) | $-80.45M | $1.64M |
| Gross margin | 76.19% | 53.97% |
| Operating margin | -38.30% | -0.61% |
| Net margin | -33.60% | 0.19% |
| 52-week high | $35.87 | $31.75 |
| 52-week low | $15.59 | $17.83 |
| Distance from 52-week high | -32.48% | -27.18% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +17.92% | +39.49% |
| Average volume | 835.89K | 3.64M |
| Shares outstanding | 50.20M | 108.80M |
| Employees | 921 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Warby Parker is about 2.4 times larger than STAAR Surgical by market value ($2.87B vs $1.22B).
- WRBY has outperformed STAA by 40.0 percentage points over the past year.
- Warby Parker is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -33.6 cents for STAAR Surgical.
- Warby Parker grew revenue faster in its latest fiscal year (+13.04% vs -23.72%).
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
About Warby Parker
WRBY stock →Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada.
Health Care · Ophthalmic Goods · 2,275 employees
STAA vs WRBY FAQ
Which is bigger, STAAR Surgical or Warby Parker?
Warby Parker (WRBY) is larger, with a market capitalization of $2.87B compared with $1.22B for STAAR Surgical (STAA).
Which stock has performed better over the past year, STAA or WRBY?
WRBY returned +26.48% over the past 12 months, compared with -13.50% for STAA (price return, excluding dividends). Past performance does not predict future results.
Are STAAR Surgical and Warby Parker in the same industry?
Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.